These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 4443613)

  • 21. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The determination of the optimal inoculation dose of an oral cholera chemical bivalent vaccine in a controlled experiment].
    Sumarokov AA; Ivanov NR; Dzhaparidze MN; Reznikov IuB; Rystsova EA; Nikitina GP; Matusevich LIa; Popov AA; Plotnikova MN; Shustov VIa
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Dec; (12):55-62. PubMed ID: 2099071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experimental justification for combined subcutaneous immunization against cholera and typhoid fever].
    Gapochko KG; Emel'ianova OV; Ziablitsev IF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):85-9. PubMed ID: 6702364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of oral cholera vaccines during pregnancy in developing countries.
    Khan AI; Islam MT; Qadri F
    Hum Vaccin Immunother; 2017 Oct; 13(10):2245-2246. PubMed ID: 28825876
    [No Abstract]   [Full Text] [Related]  

  • 25. Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine.
    Chac D; Bhuiyan TR; Saha A; Alam MM; Salma U; Jahan N; Chowdhury F; Khan AI; Ryan ET; LaRocque R; Harris JB; Qadri F; Weil AA
    Infect Immun; 2021 Aug; 89(9):e0021721. PubMed ID: 34228490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal.
    Albert MJ; Alam K; Rahman AS; Huda S; Sack RB
    J Infect Dis; 1994 Mar; 169(3):709-10. PubMed ID: 8158063
    [No Abstract]   [Full Text] [Related]  

  • 27. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.
    Attridge SR; Rowley D
    J Infect Dis; 1983 Nov; 148(5):931-9. PubMed ID: 6195273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
    Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
    J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness of vaccination against cholera and typhoid fever.
    Germanier R
    Monogr Allergy; 1975; 9():217-30. PubMed ID: 1090807
    [No Abstract]   [Full Text] [Related]  

  • 30. [Serologic response in man to cholera vaccine].
    Di Tommaso I
    Ann Sclavo; 1973; 15(4):445-52. PubMed ID: 4788453
    [No Abstract]   [Full Text] [Related]  

  • 31. Cholera vaccine inactivated oral.
    Drugs R D; 1999 Sep; 2(3):193-4. PubMed ID: 10641223
    [No Abstract]   [Full Text] [Related]  

  • 32. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunity in cholera.
    Ghosh AK
    Indian J Pathol Bacteriol; 1974 Apr; 17(2):118-25. PubMed ID: 4455619
    [No Abstract]   [Full Text] [Related]  

  • 34. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
    Migasena S; Pitisuttitham P; Supanaranond W; Desakorn V; Prayurahong B; Suntharasamai P
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):423-8. PubMed ID: 3217824
    [No Abstract]   [Full Text] [Related]  

  • 36. [Serological response in man to an anticholera vaccine made from killed vibrios and partially purified with aluminium hydroxide].
    Soscia M; Saletti M; Ricci A; Di Gioia M
    Ann Sclavo; 1975; 17(3):257-66. PubMed ID: 1230039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitoxic immunity to cholera in dogs immunized orally with cholera toxin.
    Pierce NF; Cray WC; Engel PF
    Infect Immun; 1980 Feb; 27(2):632-7. PubMed ID: 7380543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.
    Pierce NF; Cray WC; Sacci JB
    Infect Immun; 1982 Aug; 37(2):687-94. PubMed ID: 6889574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.